Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL10972899 | 0.87 | SMN1; SMN2 (0.64) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL826020 | 0.86 | KMT2A (0.53) | KMT2AALDH1A1LMNASMN1; SMN2HPGD | |
| SCHEMBL17335992 | 0.85 | CYP3A4 (0.63) | KMT2AMEN1ALDH1A1LMNANPC1 | |
| SCHEMBL13932527 | 0.84 | KMT2A (0.83) | KMT2AMEN1ALDH1A1LMNANPC1 | |
| SCHEMBL12326826 | 0.84 | KMT2A (0.62) | KMT2AMEN1ALDH1A1LMNANPC1 | |
| SCHEMBL934531 | 0.84 | TRPV1 (0.54) | KMT2AMEN1ALDH1A1USP2HPGD | |
| SCHEMBL21648724 | 0.84 | EPHX2 (0.51) | ALDH1A1LMNAHPGD | |
| SCHEMBL13181415 | 0.84 | KMT2A (0.61) | KMT2AALDH1A1RAB9AHPGDPOLB | |
| SCHEMBL13024401 | 0.84 | TPSAB1 (0.50) | ALDH1A1LMNATDP1HPGD | |
| SCHEMBL23564742 | 0.82 | KMT2A (0.65) | KMT2AMEN1ALDH1A1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023225568-A1 | METHODS FOR IDENTIFYING REACTIVE FUNCTIONAL CYSTEINES IN NUCLEAR PROTEINS | TALUS BIOSCIENCE, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200131140-A1 | CONTROLLED CYCLIZATION OF PEPTOIDS TO FORM CHIRAL DIKETOPIPERAZINES | TRIAD NATIONAL SECURITY, LLC (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-9353120-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-05-31 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150316658-A1 | CONTRAST AGENT FOR OPTICAL IMAGING, USE THEREOF AND APPARATUS USING THE SAME | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-11-05 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| EP-0473225-B1 | Process for iodinating or brominating the alpha-methylenic carbon of a 3-oxo-4aza-steroid | MERCK & CO INC (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5120847-A | Chemical intermediate which can be dehydrohalogenation | MERCK & CO., INC. (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0473225-A2 | Process for iodinating or brominating the alpha-methylenic carbon of a secondary amide | MERCK & CO. INC. (US) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | KMT2A 2755/4885MEN1 903/4885ALDH1A1 1477/4885 |
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | KMT2A 2953/4885MEN1 1785/4885ALDH1A1 1104/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | KMT2A 4200/4885MEN1 3610/4885ALDH1A1 968/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | KMT2A 2953/4885MEN1 1785/4885ALDH1A1 1104/4885 |
| US-20200131140-A1 | CONTROLLED CYCLIZATION OF PEPTOIDS TO FORM CHIRAL DIKETOPIPERAZINES | NPPA, NPEPPS, RRP15 | KMT2A 2599/4885MEN1 3212/4885ALDH1A1 4849/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | KMT2A 4200/4885MEN1 3610/4885ALDH1A1 968/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | KMT2A 2953/4885MEN1 1785/4885ALDH1A1 1104/4885 |
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | KMT2A 4698/4885MEN1 4463/4885ALDH1A1 2222/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | KMT2A 2755/4885MEN1 903/4885ALDH1A1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.